Spots Global Cancer Trial Database for Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Official Title: A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas

Study ID: NCT00348790

Conditions

Brain and Central Nervous System Tumors

Sarcoma

Interventions

vatalanib

Study Description

Brief Summary: RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with recurrent or progressive meningioma.

Detailed Description: OBJECTIVES: Primary * Determine the efficacy of vatalanib, in terms of radiographic improvement and clinical improvement, in patients with recurrent or progressive meningioma. Secondary * Determine the 6-month progression-free survival of these patients. * Describe the response rate and overall survival of these patients. * Determine the safety of vatalanib in these patients. * Correlate the response rates with expression of vascular endothelial growth factor, epidermal growth factor receptor, platelet-derived growth factor, and HER2. * Develop exploratory data concerning surrogate markers of angiogenic activity in vivo using magnetic resonance perfusion. OUTLINE: Patients receive oral vatalanib twice daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 1 year. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.